Table 2. Laboratory characteristics of essential thrombocytosis (n = 69) and primary myelofibrosis (n = 146) patients according to mutation profiles in this study.
| N (%) | Age (yr) | M:F (% males) | Hemoglobin (g/dL) | Hematocrit | Total WBC count (x109/L) | Platelet count (x109/L) | LDH (U/L)a | |
|---|---|---|---|---|---|---|---|---|
| ET (mutation-positive) | 51 (74) | 42 (12-78) | 24:27 (47) | 12.9 (8.9-16) | 39.6 (27.5-47.5) | 10.2 (5.2-55) | 875 (462-2,368) | 622 (338-3820) |
| ET (mutation-positive) JAK2 | 26 (37.6) | 46 (12-78) | 11:15 (42.3) | 12.8 (10.1-15.7) | 39.8 (31.3-47.5) | 11.3 (5.2-36.3) | 779 (462-1,856) | 601.5 (401-3820) |
| CALR | 23 (33.3) | 37 (24-65) | 12:11 (52) | 12.9 (8.9-16) | 39.2 (27.5-46.4) | 9.6 (5.8-55) | 1,045 (657-2,368) | 629 (423-1589) |
| MPL | 2 (2.9) | (66, 62) | 01:01 | 13.1 | 39.1 (38.7-39.6) | 6.7 (5.4-8.1) | 716 (672-760) | 569 |
| Triple-negative ET | 18 (26) | 18 (1-60) | 7:11 (38.8) | 11.9 (9.5-14.3) | 35.6 (29.5-43.5) | 10.2 (4.4-15.4) | 1,190 (622-2,708) | 618 (338-1,117) |
| (Mutated vs. triple-negative) p value* | - | 0.002 | 0.54 | 0.001 | 0.0002 | 0.58 | 0.02 | 0.8 |
| (JAK2V617F vs. CALR) p value* | - | 0.42 | 0.48 | 0.91 | 0.25 | 0.02 | 0.01 | 0.56 |
| (CALR vs. triple-negative) p value* | - | 0.002 | 0.54 | 0.01 | 0.009 | 0.09 | 0.32 | 0.8 |
| (JAK2 vs. triple-negative) p value* | - | 0.001 | 0.82 | 0.004 | 0.0001 | 0.36 | 0.004 | 0.98 |
| PMF (mutation-positive) | 124 (85) | 54 (31-80) | 87:38 (69.6) | 9.6 (3.7-15.8) | 29.9 (11.6-54.2) | 8.7 (1.8-197.4) | 243 (7-1664) | 1,162 (403-3,896) |
| PMF (mutation-positive) JAK2 | 70 + 2b (47.9 + 1.4) | 55 (36-80) | 47:23 (67) | 9.85 (3.8-15.8) | 31.3 (11.6-54.2) | 11.5 (1.8-152.5) | 211.5 (7-1664) | 1,144 (403-3,687) |
| CALR | 48 (32.8) | 50 (31-76) | 36:12 (75) | 10.1 (3.7-14.7) | 29.9 (11.7-44.4) | 7.85 (2.5-197.4) | 295.5 (9-1565) | 1,235 (562-3,896) |
| MPL | 4 (2.7) | 61 (51-74) | 02:02 | 8 (7.6-9.2) | 25.7 (24-28.4) | 5.35 (4.2-21.7) | 104.5 (63-342) | 1,490.5 (1,157-2,700) |
| Triple-negative PMF | 22 (15) | 42 (14-64) | 16:6 (72.7) | 8.4 (5.9-14.7) | 27.9 (18.3-42.5) | 7 (1.3-66.5) | 87.5 (7-1371) | 723.5 (241-1803) |
| (Mutated vs. triple-negative) p value* | - | 0.002 | 0.76 | 0.07 | 0.17 | 0.41 | 0.02 | 0.001 |
| (JAK2V617F vs. CALR) p value* | - | 0.013 | 0.84 | 0.81 | 0.66 | 0.07 | 0.01 | 0.24 |
| (CALR vs. triple- negative) p value* | - | 0.026 | 0.83 | 0.95 | 0.94 | 0.42 | 0.68 | 0.002 |
| (JAK2 vs. triple-negative) p value* | - | <0.00001 | 0.62 | 0.09 | 0.17 | 0.16 | 0.1 | 0.006 |
Note. CALR = calreticulin; ET = essential thrombocytosis; LDH = lactate dehydrogenase; MPL = ; PMF = primary myelofibrosis; WBC = white blood cell.
* All p values were calculated using the v2 test for categorical variables and the Mann-Whitney U test for continuous variables in patients with ET and PMF with mutations in either of the driver genes and JAK2-mutated ET or PMF versus CALR-mutated ET or PMF. Significant values are in boldface.